Acute Interstitial PneumoniaSymptoms, Doctors, Treatments, Advances & More
Acute Interstitial Pneumonia Overview
Learn About Acute Interstitial Pneumonia
- Acute interstitial pneumonia
- Acute interstitial pneumonitis
- Hamman-Rich syndrome
UPMC Comprehensive Lung Center - Simmons Center
Kevin Gibson, MD, specializes in interstitial lung disease and is board-certified in pulmonary disease and internal medicine by the American Board of Internal Medicine. He practices at UPMC Comprehensive Lung Center - Simmons Center and is affiliated with University of Pittsburgh Physicians, Department of Medicine and UPMC Presbyterian. Dr. Gibson completed his medical degree at University of Medicine and Dentistry of New Jersey, residency at Emory University School of Medicine, and fellowship at the University of Pittsburgh School of Medicine.Dr. Gibson specializes in treating patients with idiopathic pulmonary fibrosis, sarcoidosis, autoimmune lung disease, and occupational lung disease. Dr. Gibson is rated as an Elite provider by MediFind in the treatment of Acute Interstitial Pneumonia. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, and Lung Transplant. Dr. Gibson is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Gibson is currently accepting new patients.
Inova Medical Group - Transplant Specialties
Oksana A. Shlobin, MD, FCCP, serves as Medical Director for the Pulmonary Hypertension Program and Director of Outreach and Education for the Inova Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital. She is also an Associate Professor of Clinical Medicine at Georgetown University School of Medicine and an Associate Clinical Professor of Medicine at the University of Virginia. Dr. Shlobin is board certified in pulmonary and critical care medicine. Dr. Shlobin has been actively involved in clinical research both during her fellowship and her tenure at Inova. She is co-author of multiple publications, including original research manuscripts, abstracts and book chapters. Her research interests include pulmonary hypertension and interstitial lung diseases. Blog Posts What is Pulmonary Hypertension? Learn the Facts to Breathe Easy (November 2018) Pulmonary Hypertension is Serious. Learn to Spot the Signs (May 2017). Dr. Shlobin is rated as an Elite provider by MediFind in the treatment of Acute Interstitial Pneumonia. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Pulmonary Hypertension, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Endoscopy.
Baylor College Of Medicine - Pulmonary
Ivan Rosas, MD, is dedicated to delivering high-quality, compassionate care to Houston and nearby communities. Ivan Rosas specializes in Pulmonary Disease and works at BCM - Faculty Group Practice. To make an appointment, please call (713) 798-2400. To review all accepted insurance carriers, please visit: https://www.stlukeshealth.org/patients-visitors/patients/billing-insurance/insurances-accepted. Dr. Rosas is rated as an Elite provider by MediFind in the treatment of Acute Interstitial Pneumonia. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, and Lung Transplant. Dr. Rosas is currently accepting new patients.
Summary: This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD). The purpose of this study is to compare whether imaging patterns from high-resolution computed tomography (HRCT) at baseline can predict worsening. Single Time point Prediction (STP) is a score derived from an artificial intelligenc/ machine learning (A...
Summary: This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in subjects with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center


